non-alcoholic fatty liver disease

Also found in: Wikipedia.

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.

Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Pathogenesis
Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.

Mentioned in ?

References in periodicals archive ?

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterised by liver cell (hepatocyte) damage, liver inflammation and fibrosis that can progress to cirrhosis, liver failure, cancer and death.

Akero Therapeutics treats first patient with NASH in Phase 2a Study of AKR-001

Non-alcoholic fatty liver disease. In: Feldman M, Frieddman LS, Brandt LJ, eds.

STUDY OF PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS ASSOCIATION WITH TYPE 2 DIABETES MELLITUS IN A TERTIARY CARE HOSPITAL

[USA], Jun 8 (ANI): In a major relief to paediatric Non-Alcoholic Fatty Liver Disease (NAFLD) patients, a new blood test could become clinical practice within five years, reducing the need for a liver biopsy in the patients.

New blood test on horizon for paediatric liver disease

Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of people in the West and is the most common cause of liver disease around the world.

Diabetes could be predictor of later liver issues; HEALTH

Dr Jameel Ahmed, Professor of medicine at the Baqai Medical University, spoke on non-alcoholic fatty liver disease and informed that weight loss through exercise, diet control and living an active life could prevent people from fatty liver disease, which later converted into chronic liver disease and other fatal complications.

Experts call for mass screening for hepatitis C

The non-alcoholic fatty liver disease activity score, the clinical measure of NASH activity, improved in the majority of animals treated with the combination of larazotide/OCA when compared to vehicle.

Innovate Biopharmaceuticals larazotide shows improvements in NASH biomarkers

Promethera is pioneering the use of liver-derived stem cells for the treatment of ACLF and non-alcoholic fatty liver disease (NASH).

Promethera Biosciences To Present Data From Clinical Trial In Liver Failure

On the other hand, non-alcoholic fatty liver disease (NA-FLD) as a subclass of fatty liver disease has become one of the major public health problems as it increases the risk of liver cirrhosis, liver cancer, and metabolic disorders and is regarded as a metabolic syndrome (MetS) exhibited by the liver (1).

Evaluation of neck circumference as an easy and reliable predictor for non-alcoholic fatty liver disease

Summary: Non-alcoholic fatty liver disease causing increasing liver damage among UAE residents

'Silent' liver condition presents major threat among UAE residents

The result is an epidemic crisis of non-alcoholic fatty liver disease (NAFLD).

Promote LIVER Detoxification

Abdominal obesity is a criteria of the metabolic syndrome, also called pre-diabetes, which is a cluster of abnormalities characterized by insulin resistance, inflammation, oxidative stress, hypertension and dyslipidaemia which carries increased risk of type 2 diabetes mellitus(T2DM), cardiovascular disease, non-alcoholic fatty liver disease (NAFLD) and cancer (Kopelman, 2000; Eckel et al, 2005; Grattagliano et al., 2008).

La Vitamina E Protege contra el Dano Ultraestructural de los Hepatocitos Inducido por la Dieta Alta en Grasas en un Modelo de Pre-diabetes en Ratas

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk